Latest Healthcare It News

RAM Essential Services Property Fund (REP) reports a Q1 FY26 distribution in line with guidance and reaffirms its full-year yield target while progressing its strategic transition to a healthcare-focused REIT.

Australian Clinical Labs has reached a $6.2 million settlement with the Australian Information Commissioner to resolve a Federal Court case stemming from a 2022 cyberattack on its newly acquired Medlab Pathology business.

Mayne Pharma’s innovative oral contraceptive NEXTSTELLIS® has secured reimbursement under Australia’s Pharmaceutical Benefits Scheme, making it significantly more affordable and broadening contraceptive options nationwide.

ReNerve Ltd is rapidly advancing its nerve repair product portfolio, with four ranges expected on the market by the end of 2025 and expanding global distribution. Clinical studies highlight significant patient benefits, supporting the company’s growth in a booming biomaterials market.

Vection Technologies reports a 60% revenue surge in 1H25, secures a $21 million equity raise, and strengthens its position in defence AI and spatial computing with a robust $75 million sales pipeline.

Vection Technologies has secured $21 million through an upsized placement driven by strong defence sector momentum and announced a binding offer to acquire digital transformation firm DXLabs, bolstering its revenue and growth prospects.

Uscom Limited’s shares have been suspended from trading on the ASX due to concerns over its financial health, following a critical auditor’s disclaimer. The suspension will remain until the company meets regulatory requirements.

EMVision Medical Devices launches a $2 million Share Purchase Plan offering shares at a 16.4% discount, bundled with free options exercisable at $3.40, aiming to bolster clinical and commercial milestones.

Synlait Milk Limited reports a modest profit turnaround in FY25 and announces a major sale of its North Island assets to Abbott, aiming to reduce debt and sharpen its focus on core operations.

Synlait has agreed to sell its North Island assets to global healthcare giant Abbott for approximately US$178 million, marking a strategic reset focused on debt reduction and operational simplification. The deal, expected to close by April 2026, positions Synlait to concentrate on its South Island operations and explore new growth avenues.

Elanor Investors Group has obtained a crucial ASX waiver allowing a longer timeframe to issue securities tied to its $125 million recapitalisation with Rockworth Investment. This move addresses regulatory delays and aims to stabilise Elanor's balance sheet and reduce gearing.

INOVIQ Limited has obtained exclusive worldwide rights to novel ovarian cancer biomarker IP from UniQuest, propelling its EXO-OC™ test closer to commercial launch. The test’s exceptional sensitivity and specificity position it as a potential breakthrough in early cancer detection.